Home / Market News / $HIMS
benzinga Corporate Catalyst Impact 65/100 ● neutral

Hims Launches Injectable And Oral Testosterone Replacement Therapies

Oct 21, 2026, 12:22 PM UTC · Primary ticker $HIMS

Hims' expansion into injectable and oral testosterone replacement therapies could significantly broaden its addressable market and revenue streams, intensifying competition in the men's health sector. This move positions Hims as a more comprehensive telehealth provider, potentially attracting new subscribers and increasing customer lifetime value.

Hims' entry into injectable and oral testosterone replacement therapies represents a strategic expansion beyond its current offerings, tapping into a growing men's health market. This could significantly boost HIMS's revenue and subscriber growth, solidifying its position as a leading telehealth platform. Key risks include regulatory scrutiny, competition from established pharmaceutical companies like Endo International (ENZ) and Myovant Sciences (MYOV), and the potential for adverse public perception regarding TRT. The healthcare services and pharmaceutical sectors will feel the most direct impact, with HIMS potentially gaining market share while competitors face increased pressure. Trading implications suggest a positive outlook for HIMS, while companies with existing TRT products may experience some headwinds.

$HIMS positive New product launch, market expansion
$ENZ negative Increased competition in TRT market
$MYOV negative Potential competition for men's health offerings
$TDOC neutral Broader telehealth competitor, but not direct TRT focus
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.